Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.
Hemogenyx Pharmaceuticals announced the successful treatment of the first patient in its Phase I clinical trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (AML). The treatment showed a favorable safety profile with no adverse effects, marking a significant milestone for the company. The trial aims to assess the safety and efficacy of HG-CT-1, with early signs of efficacy being encouraging. This development could potentially address a critical need for patients with limited treatment options, enhancing Hemogenyx’s position in the biopharmaceutical industry.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new treatments for blood and autoimmune diseases, aiming to expand the curative potential of bone marrow transplantation for patients with life-threatening conditions. Hemogenyx is engaged in creating several product candidates and a platform technology for novel product development.
YTD Price Performance: -55.49%
Average Trading Volume: 32,925
Technical Sentiment Signal: Buy
Current Market Cap: £7.38M
See more insights into HEMO stock on TipRanks’ Stock Analysis page.